MedTrace Logo

A Single Dose, Phase 1 Study of YH35324 in Patients with Various Allergic Diseases

NCT05960708 · Status: COMPLETED · Phase: PHASE1 · Type: INTERVENTIONAL · Enrollment: 30

Last updated 2024-11-22

No results posted yet for this study

Summary

This study aims to evaluate the safety, tolerability, pharmacokinetics (PK), and pharmacodynamics (PD) following a single subcutaneous injection of YH35324 in subjects with various allergic diseases.

Conditions

Interventions

DRUG

YH35324

Subcutaneous injection of YH35324

DRUG

Omalizumab

Subcutaneous injection of Omalizumab

DRUG

Placebo

Subcutaneous injection of None of active ingredient

Sponsors & Collaborators

  • Yuhan Corporation

    lead INDUSTRY

Principal Investigators

  • Hae-Sim Park · Ajou University School of Medicine

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
QUADRUPLE
Model
PARALLEL

Eligibility

Min Age
19 Years
Max Age
75 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2023-08-23
Primary Completion
2024-09-13
Completion
2024-09-13

Countries

  • South Korea

Study Locations

More Related Trials

Entities

Drugs
Diseases

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT05960708 on ClinicalTrials.gov